An Open-label, Multicenter Phase II Clinical Study of SHR-A2102 for Injection in the Treatment of Advanced Gynaecological Malignancies
Latest Information Update: 16 Dec 2024
At a glance
- Drugs SHR A2102 (Primary)
- Indications Gynaecological cancer
- Focus Therapeutic Use
- Sponsors Shanghai Hengrui Pharmaceutical
Most Recent Events
- 10 Dec 2024 Status changed from not yet recruiting to recruiting.
- 28 Oct 2024 New trial record